LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,089
تعداد مقالات9,995
تعداد مشاهده مقاله26,203,755
تعداد دریافت فایل اصل مقاله7,238,248
Azadi, Soha, Shahabinezhad, Farbod, Shafiekhani, Mojtaba. (1401). Drug-related Problems in Solid-Organ Transplant Recipients Hospitalized for COVID-19: An Experience of a Referral Tertiary Center in Iran. سامانه مدیریت نشریات علمی, 47(6), 577-587. doi: 10.30476/ijms.2022.93366.2467
Soha Azadi; Farbod Shahabinezhad; Mojtaba Shafiekhani. "Drug-related Problems in Solid-Organ Transplant Recipients Hospitalized for COVID-19: An Experience of a Referral Tertiary Center in Iran". سامانه مدیریت نشریات علمی, 47, 6, 1401, 577-587. doi: 10.30476/ijms.2022.93366.2467
Azadi, Soha, Shahabinezhad, Farbod, Shafiekhani, Mojtaba. (1401). 'Drug-related Problems in Solid-Organ Transplant Recipients Hospitalized for COVID-19: An Experience of a Referral Tertiary Center in Iran', سامانه مدیریت نشریات علمی, 47(6), pp. 577-587. doi: 10.30476/ijms.2022.93366.2467
Azadi, Soha, Shahabinezhad, Farbod, Shafiekhani, Mojtaba. Drug-related Problems in Solid-Organ Transplant Recipients Hospitalized for COVID-19: An Experience of a Referral Tertiary Center in Iran. سامانه مدیریت نشریات علمی, 1401; 47(6): 577-587. doi: 10.30476/ijms.2022.93366.2467

Drug-related Problems in Solid-Organ Transplant Recipients Hospitalized for COVID-19: An Experience of a Referral Tertiary Center in Iran

Iranian Journal of Medical Sciences
مقاله 9، دوره 47، شماره 6، بهمن 2022، صفحه 577-587    اصل مقاله (269.09 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2022.93366.2467
نویسندگان
Soha Azadi1؛ Farbod Shahabinezhad1؛ Mojtaba Shafiekhani* 1، 2، 3
1Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
2Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3Shiraz Transplant Center, Abu-Ali Sina Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Transplanted patients receiving immunosuppressive agents are at a higher risk of Coronavirus-disease-2019 (COVID-19), and their polypharmacy state makes the choice of treatment challenging. This study aimed to assess the drug-related problems (DRP) and clinical pharmacists’ interventions to manage transplanted patients and candidates for transplantation with COVID-19. 
Methods: This cross-sectional study was conducted in the COVID-19 intensive care unit of Shiraz Organ Transplantation Center (Iran), from March 2020 to April 2021. Patients were admitted to the COVID-19 intensive care unit based on clinical symptoms or positive polymerase chain reaction (PCR) tests. The clinical pharmacist reviewed all medications and physicians’ orders on a daily basis and evaluated DRPs in accordance with the pharmaceutical care network of Europe (PCNE) classification (V 8.01). The treatment team was informed of the DRPs, and the acceptance or rejection of the intervention was also documented. Data were analyzed using SPSS (Version 25.0). In order to determine the proportion and determinants of drug-related problems, descriptive statistics and logistic regression were applied, respectively.
Results: A clinical pharmacist reviewed 631 individuals with 11770 medication orders, and 639 DRPs were found in 69% of them with an average of 1.01±1 per patient. The most commonly reported DRPs were treatment efficacy issues followed by adverse drug reactions (ADRs). A total of 982 interventions were provided at prescriber, patient, and drug levels, of which 801 were accepted, and 659 (82.27%) were fully implemented. 
Conclusion: There have been considerable drug-related issues in managing transplanted patients with COVID-19. DRPs are more common in people with polypharmacy, more than three comorbidities, and hydroxychloroquine regimens.
کلیدواژه‌ها
COVID-19؛ Clinical pharmacists؛ Kidney transplantations؛ Liver transplantations
سایر فایل های مرتبط با مقاله
مراجع
  1. Organization WH [Internet]. Coronavirus disease (COVID-2019) situation reports 2020 2020 [cited 20 May 2021]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
  2. Mirjalili M, Shafiekhani M, Vazin A. Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen. Ther Clin Risk Manag. 2020;16:617-29. doi: 10.2147/TCRM.S256246. PubMed PMID: 32694915; PubMed Central PMCID: PMCPMC7340365.
  3. Fernandez-Ruiz M, Andres A, Loinaz C, Delgado JF, Lopez-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. Am J Transplant. 2020;20:1849-58. doi: 10.1111/ajt.15929. PubMed PMID: 32301155.
  4. Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant. 2020;20:1800-8. doi: 10.1111/ajt.15941. PubMed PMID: 32330343; PubMed Central PMCID: PMCPMC7264777.
  5. Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020;55:105945. doi: 10.1016/j.ijantimicag.2020.105945. PubMed PMID: 32194152; PubMed Central PMCID: PMCPMC7156117.
  6. Amariles P, Hincapie-Garcia J, Julio Montoya C. Pharmacotherapy for hospitalized patients with COVID-19: Waiting or doing? Res Social Adm Pharm. 2021;17:2049. doi: 10.1016/j.sapharm.2020.05.010. PubMed PMID: 32405278; PubMed Central PMCID: PMCPMC7219394.
  7. Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020;72:287-304. doi: 10.1002/hep.31281. PubMed PMID: 32298473; PubMed Central PMCID: PMCPMC7262242.
  8. Shafiekhani M, Shahabinezhad F, Niknam T, Tara SA, Haem E, Mardani P, et al. Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand? Virol J. 2021;18:228. doi: 10.1186/s12985-021-01700-2. PubMed PMID: 34809657; PubMed Central PMCID: PMCPMC8607221.
  9. Bartiromo M, Borchi B, Botta A, Bagala A, Lugli G, Tilli M, et al. Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19). Transpl Infect Dis. 2020;22:e13286. doi: 10.1111/tid.13286. PubMed PMID: 32279418; PubMed Central PMCID: PMCPMC7262190.
  10. van Mil F. Drug-related problems: a cornerstone for pharmaceutical care. Journal of the Malta College of Pharmacy Practice 2005;10:5-8. 
  11. Hailu BY, Berhe DF, Gudina EK, Gidey K, Getachew M. Drug related problems in admitted geriatric patients: the impact of clinical pharmacist interventions. BMC Geriatr. 2020;20:13. doi: 10.1186/s12877-020-1413-7. PubMed PMID: 31931723; PubMed Central PMCID: PMCPMC6958579.
  12. Rezazadeh A, Hajimiri SH, Kebriaeezadeh A, Gholami K, Hashemian F, Khoshnevisan A, et al. Clinical and economic impact of comprehensive medication management implementation by clinical pharmacists in an intensive care unit: a cost–benefit analysis. Journal of Pharmaceutical Health Services Research. 2021;12:460-2. doi: 0.1093/jphsr/rmab026.
  13. Shafiekhani M, Tarighati S, Mirzaei E, Namazi S. Evaluation and management of drug-drug interactions in patients hospitalized in nephrology and post-transplant wards in a teaching hospital. Journal of Pharmaceutical Care. 2020. doi: 10.18502/jpc.v8i1.2742.
  14. Shafiekhani M, Moosavi N, Firouzabadi D, Namazi S. Impact of Clinical Pharmacist’s Interventions on Potential Drug-Drug Interactions in the Cardiac Care Units of Two University Hospitals in Shiraz, South of Iran. J Res Pharm Pract. 2019;8:143-8. doi: 10.4103/jrpp.JRPP_18_88. PubMed PMID: 31728345; PubMed Central PMCID: PMCPMC6830024.
  15. Visacri MB, Figueiredo IV, Lima TM. Role of pharmacist during the COVID-19 pandemic: A scoping review. Res Social Adm Pharm. 2021;17:1799-806. doi: 10.1016/j.sapharm.2020.07.003. PubMed PMID: 33317760; PubMed Central PMCID: PMCPMC7334137.
  16. Elbeddini A, Yeats A. Pharmacist intervention amid the coronavirus disease 2019 (COVID-19) pandemic: from direct patient care to telemedicine. J Pharm Policy Pract. 2020;13:23. doi: 10.1186/s40545-020-00229-z. PubMed PMID: 32501410; PubMed Central PMCID: PMCPMC7251049.
  17. Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020;97:1076-82. doi: 10.1016/j.kint.2020.03.018. PubMed PMID: 32354637; PubMed Central PMCID: PMCPMC7142878.
  18. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45. doi: 10.1038/clpt.1981.154. PubMed PMID: 7249508.
  19. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230. doi: 10.1186/s12877-017-0621-2. PubMed PMID: 29017448; PubMed Central PMCID: PMCPMC5635569.
  20. Europe PCN. PCNE Classification for Drug-Related Problems V8. 01. 2017. Benelux: Europe PCN; 2018. 
  21. Koubaity M, Lelubre M, Sansterre G, Amighi K, De Vriese C. Adaptation and validation of PCNE drug-related problem classification v6.2 in French-speaking Belgian community pharmacies. Int J Clin Pharm. 2019;41:244-50. doi: 10.1007/s11096-018-0773-y. PubMed PMID: 30610541.
  22. Lin HW, Lin CH, Chang CK, Chou CY, Yu IW, Lin CC, et al. Economic outcomes of pharmacist-physician medication therapy management for polypharmacy elderly: A prospective, randomized, controlled trial. J Formos Med Assoc. 2018;117:235-43. doi: 10.1016/j.jfma.2017.04.017. PubMed PMID: 28549592.
  23. Abunahlah N, Elawaisi A, Velibeyoglu FM, Sancar M. Drug related problems identified by clinical pharmacist at the Internal Medicine Ward in Turkey. Int J Clin Pharm. 2018;40:360-7. doi: 10.1007/s11096-017-0585-5. PubMed PMID: 29380236.
  24. Ritchie AI, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? Lancet. 2020;395:1111. doi: 10.1016/S0140-6736(20)30691-7. PubMed PMID: 32220278; PubMed Central PMCID: PMCPMC7138169. doi: 10.1016/S0140-6736(20)30691-7.
  25. Yousefifard M, Zali A, Ali KM, Neishaboori AM, Zarghi A, Hosseini M, et al. Antiviral Therapy inManagement of COVID-19: a Systematic Review on Current Evidence. Archives of Academic Emergency Medicine. 2020:1-9. 
  26. Garedow AW, Mulisa Bobasa E, Desalegn Wolide A, Kerga Dibaba F, Gashe Fufa F, Idilu Tufa B, et al. Drug-Related Problems and Associated Factors among Patients Admitted with Chronic Kidney Disease at Jimma University Medical Center, Jimma Zone, Jimma, Southwest Ethiopia: A Hospital-Based Prospective Observational Study. Int J Nephrol. 2019;2019:1504371. doi: 10.1155/2019/1504371. PubMed PMID: 31772774; PubMed Central PMCID: PMCPMC6854244.
  27. Blix HS, Viktil KK, Moger TA, Reikvam A. Characteristics of drug-related problems discussed by hospital pharmacists in multidisciplinary teams. Pharm World Sci. 2006;28:152-8. doi: 10.1007/s11096-006-9020-z. PubMed PMID: 17004023. 
  28. Greeshma M, Lincy S, Maheswari E, Tharanath S, Viswam S. Identification of drug related problems by clinical pharmacist in prescriptions with polypharmacy: A prospective interventional study. Journal of Young Pharmacists. 2018;10:460. doi: 10.5530/jyp.2018.10.100.
  29. Joel JJ, Shastry C. A study on drug related problems and pharmacist intervention in patients undergoing haemodialysis in a tertiary care hospital. International Research Journal of Pharmaceutical and Applied Sciences. 2013;3:263-5. 
  30. Sun J, Deng X, Chen X, Huang J, Huang S, Li Y, et al. Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System. Clin Pharmacol Ther. 2020;108:791-7. doi: 10.1002/cpt.1866. PubMed PMID: 32324898; PubMed Central PMCID: PMCPMC7264575. 
  31. Fathnin FH, Yuniastuti A. The Relation of Drug Amount, Comorbidity, Blood Pressure, and Residential Area to Drug-Related-Problems of Hypertension Patients. Public Health Perspective Journal. 2020;5. 
  32. Eichenberger PM, Haschke M, Lampert ML, Hersberger KE. Drug-related problems in diabetes and transplant patients: an observational study with home visits. Int J Clin Pharm. 2011;33:815-23. doi: 10.1007/s11096-011-9542-x. PubMed PMID: 21811831. 
  33. Bickel M, Anadol E, Vogel M, Hofmann WP, von Hentig N, Kuetscher J, et al. Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. J Antimicrob Chemother. 2010;65:999-1004. doi: 10.1093/jac/dkq054. PubMed PMID: 20202988; PubMed Central PMCID: PMCPMC2902821.
  34. Dashti-Khavidaki S, Mohammadi K, Khalili H, Abdollahi A. Pharmacotherapeutic considerations in solid organ transplant patients with COVID-19. Expert Opin Pharmacother. 2020;21:1813-9. doi: 10.1080/14656566.2020.1790526. PubMed PMID: 32659126.
  35. van Maarseveen EM, Rogers CC, Trofe-Clark J, van Zuilen AD, Mudrikova T. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. AIDS Patient Care STDS. 2012;26:568-81. doi: 10.1089/apc.2012.0169. PubMed PMID: 23025916.
  36. Pena MA, Horga JF, Zapater P. Variations of pharmacokinetics of drugs in patients with cirrhosis. Expert Rev Clin Pharmacol. 2016;9:441-58. doi: 10.1586/17512433.2016.1135733. PubMed PMID: 26696448.
آمار
تعداد مشاهده مقاله: 2,768
تعداد دریافت فایل اصل مقاله: 2,277


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب